Home › Calculator › BOIRF Dividend Calculator 2026
BOIRF DRIP Calculator & Dividend Yield 2026
4.98% YieldHealthcareBoiron S.A. · OTC
Price: $31.50 · Annual div: $1.57/share · Frequency: annual · Payout ratio: 84% · Ex-div: 2026-06-04
Calculator settings
Portfolio growth: DRIP vs No DRIP
Annual dividend income growth
💡 What-if scenarios
Click to apply scenario to the calculator
🎯 When BOIRF pays your bills
Year your monthly dividend income covers each expense (based on current settings)
BOIRF Dividend History — Last 26 Payments
| Ex-Dividend Date | Payment Date | Amount / Share | TTM Yield | Stock Price |
|---|---|---|---|---|
| 2026-06-04Latest | 2026-06-05 | $1.5698 | 4.92% | $31.90 |
| 2025-06-04 | 2025-06-05 | $1.3708 | 4.81% | $28.50 |
| 2024-06-04 | 2024-06-05 | $1.4685 | 31.66% | $39.10 |
| 2023-10-18 | 2023-10-20 | $10.9103 | 22.60% | $53.50 |
| 2023-05-31 | 2023-06-02 | $1.1810 | 5.07% | $43.37 |
| 2022-06-01 | 2022-06-03 | $1.0200 | 5.07% | $43.00 |
| 2021-06-02 | 2021-06-04 | $1.1610 | 2.48% | $46.80 |
| 2020-06-02 | 2020-06-04 | $1.1690 | — | — |
| 2019-05-30 | 2019-06-03 | $1.6140 | — | — |
| 2018-05-31 | 2018-06-04 | $1.8660 | — | — |
| 2017-05-31 | 2017-06-02 | $1.7900 | — | — |
| 2016-06-01 | 2016-06-03 | $1.6745 | — | — |
| 2015-06-03 | 2015-06-05 | $1.6720 | — | — |
| 2014-06-03 | 2014-06-06 | $1.6310 | — | — |
| 2013-05-31 | 2013-06-05 | $0.9000 | — | — |
| 2012-05-30 | 2012-06-04 | $0.7000 | — | — |
| 2011-05-31 | 2011-06-03 | $0.7000 | — | — |
| 2010-06-01 | 2010-06-04 | $0.7000 | — | — |
| 2009-06-02 | 2009-06-05 | $0.6000 | — | — |
| 1994-07-01 | 1994-07-01 | $0.4102 | — | — |
| 1993-07-01 | 1993-07-01 | $0.3482 | — | — |
| 1992-07-01 | 1992-07-01 | $0.3528 | — | — |
| 1991-07-01 | 1991-07-01 | $0.2771 | — | — |
| 1990-07-02 | 1990-07-02 | $0.2923 | — | — |
| 1989-06-30 | 1989-06-30 | $0.2636 | — | — |
| 1988-06-30 | 1988-06-30 | $0.2231 | — | — |
About Boiron S.A. (BOIRF) — Dividend Analysis 2026
Boiron S.A. is a leading pharmaceutical enterprise focused on the global development and sale of homeopathic treatments. Its market presence extends across France, the wider European continent, North America, and numerous international territories. The company's offerings comprise a diverse array of homeopathic products, including both non-proprietary and branded formulations. Notable examples from its brand portfolio target specific health concerns: Oscillococcinum is formulated to alleviate symptoms associated with influenza, such as fever, chills, headaches, and general body aches. Stodal and Stodaline are designed for the symptomatic relief of coughs. Arnigel provides topical support for minor, non-open traumatic injuries. Camilia is specifically developed to soothe teething discomfort in infants. Sédatif PC addresses anxiety, emotional imbalances, and mild sleep disturbances. Coryzalia helps manage cold symptoms and rhinitis. Homéoptic offers relief for various types of eye irritation and discomfort in both adults and children. Homéovox is aimed at vocal disorders. Beyond its core homeopathic line, Boiron provides a range of supplementary health products. These include dietary supplements; the Dermoplasmine collection (available as stick, balm, and mousse) for dry lips and skin; Mag' Nuit, designed to aid sleep; Arnitrosium for joint pain; Castor Equi Boiron ointment to treat cracked skin; and Storinil, a syrup for cold treatment. Furthermore, the company produces herbal medicines, such as Canephron, which supports increased urine production and improved urinary elimination. Its product list also features moisturizing baby milk and a selection of medical devices, including COVID-19 self-tests and rapid antigenic tests. Boiron distributes its extensive product portfolio through a wide network, encompassing its own distribution centers, independent pharmacies, large pharmacy chains, wholesalers, grocery stores, specialized health food retailers, and online sales platforms. Established in 1932, Boiron S.A. maintains its corporate headquarters in Messimy, France.
Similar dividend stocks to BOIRF
Forward dividend yield from the latest data · open any DRIP calculator
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
Get Your Full BOIRF DRIP Report by Email
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open BOIRF position with:
🌍 BOIRF Yield by Country & Account Type
Real after-tax yield depends on where you live and how you hold BOIRF.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 4.98% | 2.18% | $498 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 4.23% | 1.43% | $423 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 3.98% | 1.18% | $398 / yr |
| 🇬🇧 UK ISA | 0% | 4.98% | 2.18% | $498 / yr |
| 🇬🇧 UK Taxable | 8.75% | 4.54% | 1.74% | $454 / yr |
| 🇨🇦 TFSA | 0% | 4.98% | 2.18% | $498 / yr |
| 🇨🇦 CA Taxable | 25% | 3.74% | 0.94% | $374 / yr |
| 🇦🇺 Super (pension) | 15% | 4.23% | 1.43% | $423 / yr |
| 🇦🇺 AU Taxable | 30% | 3.49% | 0.69% | $349 / yr |
| 🇩🇪 DE Taxable | 26.375% | 3.67% | 0.87% | $367 / yr |
| 🇫🇷 FR Taxable | 30% | 3.49% | 0.69% | $349 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
🎯 BOIRF Income Goal & Break-Even
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $1.57/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
📅 BOIRF Dividend Payment Schedule
BOIRF pays annually — 1 payment per year.
📊 BOIRF vs Healthcare Benchmarks
How BOIRF compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for BOIRF sourced from FMP /financial-growth endpoint — real data, not estimates.
🏛️ BOIRF Insider Activity
No recent SEC filings reported in the last 90 days.Peer Group
Similar companies in the same sectorCompare BOIRF with peers: BOIRF vs AGYTF · BOIRF vs BJTRF · BOIRF vs CLVSF
Financial Health Scores
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the BOIRF dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
Boiron S.A. (BOIRF) is currently trading at $31.50, trading near its 52-week high. The current dividend yield is 4.98% based on an annual payout of $1.57 per share.
BOIRF (Boiron S.A.) — 4.98% Dividend Yield Analysis
Boiron S.A. (BOIRF) is a healthcare stock currently trading at $31.50 with a dividend yield of 4.98%. It pays an annual dividend of $1.57 per share. The payout ratio of 84% indicates investors should monitor dividend sustainability. Over the past 5 years, BOIRF has grown its dividend at a compound annual rate of 2.7%.
- High payout ratio (84%) — dividend cuts are possible if earnings decline.
Auto-generated from live market data. For educational purposes only — not financial advice.
Latest BOIRF News
LiveHow investors use the BOIRF dividend calculator
Illustrative examples of common use cases, written by the DividendFlow team — not customer reviews.